Collidion acquires 80% stake in Plex Pharmaceuticals

2 August 2017
mergers-acquisitions-big

USA-based Collidion has entered into a definitive agreement to acquire an 80% equity stake in Plex Pharmaceuticals (formerly known as CalAsia) in exchange for an undisclosed amount of cash and contributing a novel drug asset under development.

Under the terms of this agreement, Collidion will provide management and operational support as Plex continues its drug discovery programs, which include treatments for Parkinson's disease, glioblastoma, and cataracts. Plex's drug discovery programs have received funding through several grants from the National Institutes of Health (NIH) and the Michael J Fox Foundation for Parkinson's Research (MJFF).

"This acquisition provides Plex with a strong financial footing and enables further development of our proprietary pipeline of therapeutic candidates," said G Sridhar Prasad, Plex's president and chief scientific officer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical